Lynch expects more care-home complaints after Áras Attracta revelations

The Minister for Primary and Social Care has said she expects more concerns to be raised about care homes and disability services following the

Read More:
Áras Attracta case.

Lynch expects more care-home complaints after Áras Attracta revelations
Fri, 19 Dec, 2014 - 06:58

The Minister for Primary and Social Care has said she expects more concerns to be raised about care homes and disability services following the

Read More:

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

CONNECT WITH US TODAY

Whatsapp logo

WHATSAPP

Newsletter logo

NEWSLETTERS

Notification logo

NOTIFICATIONS

Be the first to know the latest news and updates

More in this section

Explosion at Donegal service station Planning granted for new petrol station next to site of Creeslough tragedy
Michael Lyster remembered as ‘magic in human form’ at emotional memorial service Michael Lyster remembered as ‘magic in human form’ at emotional memorial service
AI prompt chat bot. Search website to generate data, text or image. Man using computer with artificial intelligence app. Virtual Mental health experts issue warning over AI 'therapy'
CourtsCare homesPlace: TipperaryPlace: RoscreaPlace: Co TipperaryPerson: LynchPerson: Minister for Primary and Social CarePerson: MinisterPerson: Kathleen LynchEvent: AttractaOrganisation: Aras AttractaOrganisation: HSEOrganisation: Daughters of CharityOrganisation: GardaíOrganisation: Health Information and Quality AuthorityOrganisation: Prime TimeOrganisation: HIQA
<p>Sodium valproate, manufactured by Sanofi and sold as Epilim, has been linked to a high risk of serious injury for babies in the womb. File picture</p>

Three more children settle Epilim sodium valproate cases

READ NOW

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Latest

Most Read

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited